Biomarkers of left ventricular hypertrophy and remodeling in blacks

Thais Coutinho1, Malik Al-Omari, Thomas H Mosley

  • 1Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Insights

Left ventricular hypertrophy is more common in Black individuals. Biomarkers including natriuretic peptides, adrenomedullin, endothelin, and osteoprotegerin are associated with increased left ventricular mass in this population.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Research
  • Genetics and Genomics

Background:

  • Left ventricular (LV) hypertrophy is a significant risk factor for cardiovascular events.
  • LV hypertrophy disproportionately affects Black individuals, but underlying mechanisms remain unclear.
  • Understanding these mechanisms is crucial for targeted interventions.

Purpose of the Study:

  • To investigate associations between 39 candidate biomarkers and LV mass and geometry in a Black cohort.
  • To identify specific biological pathways implicated in LV hypertrophy in this population.

Main Methods:

  • Echocardiography was used to measure LV mass and index it to height.
  • LV geometry was categorized into normal, concentric remodeling, concentric hypertrophy, and eccentric hypertrophy.
  • Generalized estimating equations analyzed associations between biomarkers and LV mass index, adjusting for confounders.

Main Results:

  • N-terminal pro-brain natriuretic peptide, mid-regional pro-atrial natriuretic peptide, mid-regional pro-adrenomedullin, C-terminal pro-endothelin, and osteoprotegerin were independently associated with LV mass index.
  • These associations were primarily linked to eccentric hypertrophy.
  • Higher levels of these biomarkers correlated with increased LV mass index.

Conclusions:

  • Circulating levels of natriuretic peptides, adrenomedullin, endothelin, and osteoprotegerin are associated with increased LV mass index in Black individuals.
  • These findings offer insights into the pathophysiology of LV hypertrophy in this demographic.
  • Further research is warranted to explore therapeutic targets based on these biomarkers.